BioVersys – executive interview

In this interview, we speak with Dr Marc Gitzinger, CEO, and Hernán Levett, CFO of BioVersys, about the company’s strategy to address the growing global challenge of antimicrobial resistance through its pipeline of novel antibacterial therapies. Management outlines BioVersys’s key value drivers, led by BV100, a late-stage asset targeting carbapenem-resistant infections, one of the most critical unmet needs in hospital settings. Marc discusses the programme’s differentiated mechanism, competitive positioning and the rationale behind the upcoming Phase III trial planned for early 2026, highlighting the clinical and commercial opportunity if successful. The discussion also covers alpibectir, BioVersys’s tuberculosis programme developed in partnership with GSK. Management explains the asset’s unique mechanism, its potential role in tackling drug-resistant tuberculosis and how the 50/50 collaboration structure reduces development risk while preserving long-term value. Hernán provides insight into BioVersys’ capital strategy following its 2025 Swiss listing, including funding runway, capital allocation priorities and how the company is positioning itself to support late-stage development. The conversation concludes with management outlining key catalysts over the next 12–18 months, centred on clinical progress, partnership execution and pipeline advancement.

BioVersys (SIX: BIOV) is a Swiss clinical-stage biotechnology company developing novel antibacterial therapies to address serious, multi-drug resistant infections. Its pipeline is led by the Phase III-ready BV100 for carbapenem-resistant Acinetobacter baumannii infections in the hospital setting and alpibectir for drug-resistant tuberculosis, developed with GSK.